Supplementary Information

A General Approach for Development of Fluorogenic Probes

Suitable for No-Wash Imaging of Kinases in Live Cells

Qing Zhang, Hui Liu, Zhengying Pan*

Key Laboratory of Chemical Genomics, Key Laboratory of Structural Biology, School of Chemical Biology and Biotechnology, Peking University, Xili University Town, PKU Campus, Shenzhen, China, 518055. 86-755-26033072; panzy@pkusz.edu.cn.

Contents	Page No.
Abbreviations	2-2
Chemistry	3-19
General Information	3-3
Structures of ibrutinib and PCI-33380	3-3
Experimental Procedures and Spectroscopic Data	4-12
¹ H NMR and ¹³ C NMR Spectra of New Compounds	13-21
References	22-22
Biology	23-29
General Information	23
Fluorescent Properties Measurements	24
Mass Spectrometry Study	25
In Vitro and Live Cell Probe Labelling Experiments	25-26
Cell ViabilityAssay	26-27
Probe 1, 1R and 1S Have Similar Labelling Effects	27-28
No-Wash Imaging of Btk in Live Cells	28
Brief Video	28
Competition Study	28-29
Co-localization Study	29

Abbreviations

Boc: *tert*-butyl dicarbonate Cbz: carboxybenzyl DCM: dichloromethane DIPEA: *N,N'*-diisopropylethylamine DMF: *N,N'*-dimethylformamide EDCI: 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride Et₃N: triethylamine EtOAc: ethyl ester HATU: (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazole[4,5-b]pyridinium 3oxidhexafluorophosphate) HOBT: *N*-hydroxylbenzotriazole MeOH: methanol TFA: trifluoroacetic acid THF: tetrahydrofuran

BCR: B-cell receptor BSA: Bovine serum albumin Btk: Bruton's tyrosine kinase Btk-1: kinase domain of Bruton's tyrosine kinase (382-659)

Btk-1*: kinase domain of Bruton's tyrosine kinase (382-659, C481A)

CBB: coomassie brilliant blue staining EGFR: epidermal growth factor receptor FGS: fluorescence gel scanning GSH: glutathione IP: immunoprecipitation Itk: IL-2-inducible T-cell kinase Lck: lymphocyte-specific protein tyrosine kinase PBS: phosphate-buffered saline SDS-PAGE: sodium dodecyl sulphate-polyacrylamide gel electrophoresis

Chemistry

General Information

All reagents were purchased from commercial vendors and used without further purification. Anhydrous DMF was distilled from calcium hydride. Anhydrous DCMwas distilled from calcium hydride.

Reactions were monitored by thin-layer chromatography (TLC) carried out on 0.2 mm Jiangyou silica gel plates (HSGF₂₅₄) using UV light as visualizing agent or ninhydrin as developing agent. Flash column chromatography was carried out using Puke silica (ZCX-II, 200-300 mesh).

¹H NMR and ¹³C NMR spectra were recorded on Bruker Advance 400 and 500 spectrometers at ambient temperature. Chemical shifts are reported in ppm relativeto residual chloroform (δ_H 7.26 and δ_C 77.16) and dimethylsulfoxide (δ_H 2.50 and δ_C 39.52) as standards. Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br = broad, m = multiplet), coupling constants and number of protons. Mass spectrometric data were obtained using an AB Q-Star mass spectrometer.

Structures of ibrutinib and PCI-33380



Experimental Procedures and Spectroscopic Data



Supporting Scheme 1. Synthetic Route of Probes 1 and 2.

Compound 3.1



Compound⁵¹ (4.03 g, 0.009 mol) dissolved in 5ml DMF was added to a solution of compound³² (2.35 g, 0.008 mol) in 45 ml DMFwith K_2CO_3 (2.14 g, 0.016 mol). The

reaction mixture was heated to 80 °C and stirred overnight under nitrogen. The

reaction mixture was concentrated and extracted with ethyl acetateand water three times. The ethyl acetate layers were combined, washed with saturated NaCl, dried over anhydrous Na_2SO_4 , concentrated in vacuo and purified by flash column chromatography (Hexanes:EtOAc = 1:3) to give compound3.1 as white solids (3.71 g, yield 85%).

¹H NMR(500 MHz, CDCl₃): δ = 8.33 (d, J = 1.2 Hz, 1H), 7.63 (d, J = 6.8 Hz, 2H), 7.39-7.30 (m, 7H), 7.18-7.08 (m, 5H), 6.01 (brs, 2H), 5.51-5.47 (m, 1H), 5.22-5.06 (m, 2H), 4.62-4.54 (m, 1H), 4.27-4.18 (m, 1H), 4.02-3.96 (m, 1H), 3.71 and 3.53 (s, 3H), 2.90-2.84 (m, 2H)

¹³C NMR(125 MHz, CDCl₃): δ = 158.63, 157.75, 156.20, 155.44, 154.61, 144.24, 136.27, 129.92, 128.40, 128.01, 127.91, 127.42, 124.05, 119.53, 118.93, 98.65, 67.35, 67.26, 58.06, 57.88,52.30, 52.11,50.63, 50.36, 34.90,33.88 HRMS (m/z): [M+H]⁺ calcd. for C₃₁H₂₉N₆O₅⁺: 565.2199; found: 565.2195

Compound 4



1N LiOH (9 ml) was added slowly to a solution of compound 3.1 (1 g, 1.77 mmol) in 20 ml THF:MeOH (3:1) at room temperature. The reaction was monitored by TLC; after 2 hrs, the reaction mixture was concentrated in vacuo. The viscous mixture was extracted with ethyl acetate and water, the aqueous layers were collected, acidified

with 1N HCl to pH 3 at 0 °C, extracted with ethyl acetate.Organic layers were

combined, washed with saturated NaCl, dried over anhydrousNa $_2$ SO₄, and concentrated in vacuo to give the crude carboxylic acid.

HOBT (320.27 mg, 2.37 mmol), EDCI (1.02 g, 5.32mmol), and DIPEA (1.55 ml, 8.9 mmol) were added to a solution of the acid, followed by addition of N-(2-aminoethyl)carbamic acid *tert*-butyl ester (850 mg, 5.31 mmol) in 50 ml DCM at 0°Cunder nitrogen atmosphere. The reaction mixture was stirred overnight at room temperature. The reaction mixture was then concentrated in vacuo, and extracted with ethyl acetate and waterthree times. The organic layers were collected, washed subsequently with 1N HCl, saturated NaHCO₃, saturated NaCl, dried over anhydrous Na₂SO₄, concentrated in vacuo and purified by flash column chromatography (EtOAc with 0.5% Et₃N) togive compound4 (858 mg, yield 70%) as white solids.

¹H NMR (400 MHz, CDCl₃): δ= 8.29 (s, 1H), 7.59 (d, J = 8.4 Hz, 2H), 7.34-7.23 (m, 7H), 7.17-7.05 (m, 5H), 6.01 (brs, 2H), 5.46-5.43 (m, 1H), 5.15 (m, 2H), 4.47-4.43(m, 1H), 4.12-4.08 (m, 2H), 3.31-2.77 (m, 6H), 1.35 (s, 9H)

¹³C NMR (100 MHz, CDCl₃): δ= 158.56, 157.96, 156.25, 155.75, 154.46, 144.08, 135.90, 129.88, 129.82, 128.43, 128.12, 127.89, 127.28, 124.02, 119.49, 118.85, 98.60, 79.17, 67.58, 60.14, 54.12, 53.34, 50.53,40.00,28.24

HRMS (m/z): $[M+H]^+$ calcd. for $C_{37}H_{41}N_8O_6^+$, 693.3149; found: 693.3128

Compound 6



Ethyl glycolate (21 g, 0.202 mol) was added to a suspended solution of Na₂CO₃ (42 g, 0.396 mol) in 200 ml THF. The mixture was stirred for 1h and then 1-bromo-2,4dinitrobenzene (5 g, 0.020 mol) was added to the solution. The reaction was stirred at room temperature for 24 h. The reaction mixture was concentrated in vacuo, and partitioned with DCM and H₂O; the DCM layers were collected, washed with saturated NaCl, dried over anhydrous Na₂SO₄, concentrated in vacuo, and purified by flash column chromatography (Hexanes: EtOAc = 3:1) to give the intermediate ester as yellow solids (1.08g, yield 67% brsm).

¹H NMR (400 MHz, CDCl₃): δ = 8.74 (d, J = 2.4 Hz, 1H), 8.40 (dd, J = 9.2, 2.8 Hz, 1H), 7.01 (d, J = 9.2 Hz, 1H), 4.91 (s, 2H),4.27 (q, J = 7.2 Hz, 2H), 1.29 (t, J = 7.2 Hz, 3H) ¹³C NMR (100 MHz, CDCl₃): δ = 166.46, 155.55, 140.85, 139.20, 128.76, 121.95, 114.74, 66.31, 62.20, 14.00 HRMS (m/z): [M+Na]⁺calcd. for C₁₀H₁₀N₂O₇Na⁺, 293.0386; found: 293.0370

40 ml concentrated hydrochloric acid was added to the ester (1 g, 0.004 mol) and then the reaction mixture was heated to 100°C. The reaction was monitored by TLC, after 8 h, the reaction mixture was cooled to room temperature, poured into 300 ml water, and extracted with ethyl acetate three times. The ethyl acetate layers were collected, washed with saturated NaCl, dried over anhydrous Na₂SO₄, and concentrated in vacuo to give intermediate 6 as yellow solid and directly used in future step.

Compound 7



Methyl glycinate hydrochloride (5.1 g, 0.041 mol) was added to a suspended solution of Na₂CO₃ (10 g, 0.094 mol) in 200 ml THF. The mixture was stirred for 1 h and then 1-bromo-2,4-dinitrobenzene (5 g, 0.020 mol) was added to the solution. The reaction was stirred at room temperature for 24 h. The reaction mixture was concentrated in vacuo, and partitioned with DCM and H₂O. The DCM layerswere collected, washed with saturated NaCl, dried over anhydrous Na₂SO₄, concentrated in vacuo, and purified by flash column chromatography (Hexanes: EtOAc = 1:1) to give the intermediate as yellow solids (4.84g, yield 95%).

¹H NMR (400 MHz, CDCl₃): δ= 9.15 (d, J = 2.4 Hz, 1H), 8.94 (brs, 1H), 8.30 (dd, J = 9.2, 2.4 Hz, 1H), 6.79 (d, J = 9.2 Hz, 1H), 4.21 (d, J = 2.4 Hz, 2H), 3.87 (s, 3H) ¹³C NMR (100 MHz, CDCl₃): δ= 168.49, 147.25, 136.89, 131.16, 130.44, 124.11, 113.92, 53.04, 44.73 HRMS (m/z): [M-H]⁻ calcd. for C₉H₈N₃O₆⁻, 254.0413; found: 254.0420

39 ml 1N LiOH was added slowly to a solution of the methyl ester intermediate (1 g, 0.004 mol) in methanol. The reaction was monitored by TLC. After 2 h, the reaction mixture was concentrated, extracted with ethyl acetate and water three times. The aqueous layers were collected and acidized by 1N HCl to pH 3 at 0°C. The mixture was then extracted with dichloromethane and H₂O, washed with saturated NaCl, dried over anhydrous Na₂SO₄, and concentrated in vacuo to give intermediate 7 and directly used in future step.

Compound 8



Compound 3.1 (130 mg, 0.23 mmol) was dissolved in ethyl ester (2 ml), catalytic $Pd(OH)_2/C$ was added to the solution. After three cycles of vacuum/H₂, the reaction mixture was stirred under hydrogen atmosphere at ordinary pressure (balloon) at room temperature for 3 hrs. The reaction mixture was filtered by Celatom, the filtrate was concentrated in vacuo to get the crude intermediate and used directly in the next step.

HOBT (32.4 mg, 0.24mmol), HATU (152 mg, 0.4mmol), and Et₃N (140ul, 1mmol) were added to a solution of compound 6 (48.4 mg, 0.2mmol) and the crude intermediate from previous stepin DMF (2 ml) at 0°C under nitrogen atmosphere. The reaction mixture was stirred overnight at room temperature. Subsequently, the reaction mixture was concentrated in vacuo, extracted with ethyl acetateand water three times, the organic layers were collected, washed with 1N HCl, saturated NaHCO₃, saturated NaCl, and dried over anhydrous Na₂SO₄, concentrated in vacuo and purified by flash column chromatography (EtOAc) to yield compound 8 (65 mg, yield 50%) as yellow solid.

¹H NMR (400 MHz, CDCl₃): δ= 8.70(s, 1H), 8.36 (m, 1H), 8.28 (s, 1H), 7.61 (dd, J = 4.4, 8.4 Hz, 2H), 7.40-7.35 (m, 2H), 7.25 (d, J = 4.8 Hz, 1H), 7.19-7.06 (m, 5H), 5.60-

5.52 (m,1H), 5.03 (s, 2H), 4.84-4.71 (m, 1H), 4.33-3.97 (m, 2H), 3.66 and 3.58 (s, 3H), 3.11-2.88 (m, 2H) ¹³C NMR (100 MHz, CDCl₃): δ= 170.87, 170.44, 165.05, 164.61, 158.69, 158.63, 157.94, 155.96, 155.87, 155.65, 155.57, 154.61, 154.22, 144.53, 144.11, 140.58, 140.47, 138.64, 138.53, 129.91, 129.79, 129.06, 128.83, 127.18, 127.02, 124.12, 121.80, 121.72, 119.57, 119.54, 118.86, 118.71, 115.55, 98.65, 98.54, 68.20, 68.02, 58.02, 57.82, 54.40, 52.85, 52.52, 52.25, 52.07, 49.79 HBMS (m/z): [M+Nal⁺aalad for C → N O Na⁺ 677 1721; found: 677 1720]

HRMS (m/z): $[M+Na]^+$ calcd. for $C_{31}H_{26}N_8O_9Na^+$, 677.1721; found: 677.1720

Compound 9



Compound 4 (200 mg, 0.29 mmol) was dissolved in ethyl ester (3 ml), catalytic amount of $Pd(OH)_2/C$ was added to the solution. After three cycles of vacuum/H₂, the reaction mixture was stirred under hydrogen atmosphere (balloon) at room temperature for 3 hrs. The reaction mixture was filtered by Celatom, the filtrate was concentrated in vacuo to get the crude intermediate and used in the next step.

HOBT (47 mg, 0.35 mmol), HATU (331 mg, 0.87 mmol), and DIPEA (252 μ l, 1.45mmol) were added to a solution of compound 6 (70 mg, 0.29 mmol) and the crude intermediate from previous step in DMF (3 ml) at 0°C under nitrogen atmosphere. The reaction mixture was stirred overnight at room temperature. Subsequently, the reaction mixture was concentrated in vacuo, and extracted with ethyl acetateand water three times; the organic layers were collected, washed with 1N HCl, saturated NaHCO₃, saturated NaCl, and dried over anhydrous Na₂SO₄, concentrated in vacuo and purified by flash column chromatography (EtOAc with 0.5% Et₃N, 2% MeOH) to yield compound9 (147mg, yield 65% over two steps) as brown solids.

HRMS (m/z): [M-H]⁻calcd. for C₃₇H₃₇N₁₀O₁₀⁻, 781.2694; found: 781.2714

Probe 1



0.25 ml trifluoroacetic acid was added slowly to a solution of intermediate 9 (80 mg, 0.10 mmol) in 1 ml DCM at 0°C. The reaction was stirred at room temperature and monitored by TLC. After 3 hrs, the reaction mixture was concentrated, ethyl acetate was added, and washed with saturated NaHCO₃, saturated NaCl, dried over anhydrous Na₂SO₄, and concentrated in vacuo to give the amine as brown solids.

The coupling reagents HOBT (5 mg, 0.037 mmol), HATU (34.2 mg, 0.09 mmol), and DIPEA (26 μ l, 0.15 mmol) were added to a solution of the amine intermediate and BODIPY-FL (8.6 mg, 0.029mmol) acid in DMF at 0°C under nitrogen atmosphere. The reaction mixture was stirred overnight at room temperature. Subsequently, the reaction mixture was concentrated in vacuo, extracted with ethyl acetate and water three times; the organic layers were collected, washed with 1N HCl, saturated NaHCO₃, saturated NaCl, and dried over anhydrous Na₂SO₄, concentrated in vacuo and purified by flash column chromatography (EtOAc with 0.5% Et₃N, 5% MeOH) to yield probe 1 (5.54mg, yield 20% of two steps) as dark red solids.

¹H NMR (400 MHz, CDCl₃): δ = 8.72(d, J = 2.8 Hz, 1H), 8.40 (dd, J = 9.6, 3.2 Hz, 1H), 8.28 (d, J = 10.8 Hz, 1H), 8.15 (s, 1H), 7.82 (s, 1H), 7.68-7.61 (m, 3H), 7.56 (d, J = 9.6 Hz, 1H), 7.43 (t, J = 7.6 Hz, 2H), 7.20-7.11 (m, 5H), 7.01 (d, J = 3.6 Hz, 1H), 6.26 (t, J = 7.2 Hz, 2H), 5.54 (m, 1H), 5.39-5.18 (m, 2H), 4.39-4.35 (m, 1H), 4.19 (m, 1H), 3.97 (m, 1H), 3.19-3.00 (m, 6H), 2.76-2.67 (m, 1H), 2.59-2.60 (m, 1H), 2.42 (s, 3H), 2.40-2.38 (m, 2H), 2.24 (s, 3H).

¹³C NMR (100 MHz, CDCl₃): δ = 171.50,159.56, 158.63, 157.66, 156.78, 156.28, 144.08, 137.15, 134.92, 133.45, 130.58, 129.34, 128.83, 128.72, 128.25, 127.95, 127.60, 125.76, 124.98, 124.24, 120.72, 119.46, 119.42, 117.03, 98.16, 67.86, 66.73, 53.93, 53.39, 38.89, 38.73, 34.26,28.93, 24.38, 22.72, 14.95, 14.40, 11.45, 11.27. HRMS (m/z): [M-H]⁻calcd. for C₄₆H₄₂BF₂N₁₂O₉⁻, 955.3259; found: 955.3234.

Probe 1R and 1S were synthesized using similar procedures as probe 1.



Probe 1S

¹H NMR (400 MHz, CDCl₃): δ = 8.69(d, J = 3.2 Hz, 1H), 8.37 (dd, J = 9.3, 2.8 Hz, 1H), 8.28 (s, 1H), 8.14-8.11 (m, 1H), 7.84-7.78 (m, 1H), 7.66-7.63 (m, 2H), 7.59 (s, 1H), 7.53 (d, J = 9.5 Hz, 1H), 7.44-7.40 (m, 2H), 7.19-7.09 (m, 5H), 6.99 (d, J = 4 Hz, 1H), 6.27 (s, 1H), 6.23 (d, J = 3.96, 1H), 5.57 - 5.48 (m, 1H), 5.39-5.17 (m, 2H), 4.38-4.34 (m, 1H), 4.20-4.15 (m, 1H), 3.99-3.94 (m, 1H), 3.09-2.97 (m, 6H), 2.59-2.71(m, 2H), 2.43-2.40 (m, 5H), 2.24 (s, 3H).

HRMS (m/z): [M+Na]⁺calcd. for C₄₆H₄₃BF₂N₁₂O₉Na⁺, 979.3235; found: 979.3230.

Probe 1R

¹H NMR (400 MHz, CDCl₃): δ= 8.70(d, J = 2.8 Hz, 1H), 8.26-8.22 (m, 2H), 8.19 (brs, 1H), 7.91 (brs, 1H), 7.67-7.64 (m, 3H), 7.45-7.38 (m, 3H), 7.20-7.10 (m, 5H), 7.04 (d, J = 4 Hz, 1H), 6.30-6.27 (m, 2H), 5.62-5.59 (m, 1H), 5.31-5.24 (m, 2H), 4.58-4.56 (m, 1H), 4.14-3.99 (m, 2H), 3.22-3.03(m, 6H), 2.78-2.68 (m, 1H), 2.48-2.41(m, 6H), 2.40 (s, 3H).

HRMS (m/z): [M+Na]⁺calcd. for C₄₆H₄₃BF₂N₁₂O₉Na⁺, 979.3235; found: 979.3232.

Compound 10



Compound 4 (62 mg, 0.089mmol) was dissolved in ethyl ester (1 ml), catalytic $Pd(OH)_2/C$ was added to the solution. After three cycles of vacuum/H₂, the reaction mixture was stirred under hydrogen atmosphere (balloon) at room temperature for 3 hrs. The reaction mixture was filtered by Celatom, the filtrate was concentrated in vacuo to get the crude intermediate and used directly in the next step.

The coupling reagents HOBT (14.8 mg, 0.11 mmol), HATU (102 mg, 0.27 mmol), and DIPEA (78 µl, 0.45 mmol) were added to a solution of compound 7 (70 mg, 0.29 mmol) and the crude intermediate from the previous step in 1 ml DMF at 0°C under nitrogen atmosphere. The reaction mixture was stirred overnight at room temperature. Subsequently, the reaction mixture was concentrated in vacuo, extracted with ethyl acetate and water three times; the ethyl acetate layers were collected, washed with 1N HCl, saturated NaHCO₃, saturated NaCl, dried over anhydrous Na₂SO₄, concentrated in vacuo and purified by flash column chromatography (EtOAc with 0.5% Et₃N, 2% MeOH) to yield compound 10 (45mg, yield 65%) as brown solids.

HRMS (m/z): [M-H] calcd. for C₃₇H₃₈N₁₁O₉, 780.2854; found: 780.2871.

Probe 2



0.5 ml trifluoroacetic acid was added slowly to a solution of intermediate 10 (45 mg, 0.058mmol) in 2 ml DCM at 0°C. The reaction was stirred at room temperature and

monitored by TLC. After 3 hrs, the reaction mixture was concentrated, washed with saturated NaHCO₃, saturated NaCl, dried over anhydrous Na₂SO₄, and concentrated to give the amino intermediate as brown solids.

The coupling reagents HOBT (5 mg, 0.037 mmol), HATU (35 mg, 0.092 mmol), and DIPEA (27 μ l, 0.16 mmol) were added to a solution of the amino intermediate and BODIPY-FL (8.76 mg, 0.03 mmol) in DMF at 0°C under nitrogen atmosphere. The reaction mixture was stirred overnight at room temperature. Subsequently, the reaction mixture was concentrated in vacuo, extracted with ethyl ester and water three times,the ethyl acetate layers were collected, washed with 1N HCl, saturated NaHCO₃, saturated NaCl, dried over anhydrous Na₂SO₄, concentrated in vacuo and purified by flash column chromatography (EtOAc with 0.5% Et₃N, 5% MeOH) to yield probe 2 (5.73mg, yield 20% of two steps) as red solids.

¹H NMR (400 MHz, CDCl₃): δ = 8.26 (d, J = 3.6 Hz, 1H), 8.16(s, 1H), 7.68-7.64 (m, 3H), 7.42 (t, J = 7.6 Hz, 2H), 7.35-7.29 (m, 5H), 7.19-7.10 (m, 5H), 7.04 (d, J = 4 Hz, 1H), 6.29 (t, J = 5.6 Hz, 2H), 5.46-5.40 (m, 1H), 5.12-5.01 (m, 2H), 4.40-4.29 (m, 1H), 4.14-4.11 (m, 1H), 3.86-3.78 (m, 1H), 3.35-3.04 (m, 6H), 2.76-2.56 (m, 2H), 2.51-2.44 (m, 2H), 2.44 (s, 3H), 2.24 (s, 3H).

¹³C NMR (100 MHz, CDCl₃): δ = 173.59, 171.64, 170.86, 166.42, 165.60, 159.33, 158.52, 157.96, 157.56, 156.64, 156.24, 154.99, 154.01, 147.54, 144.22, 135.52, 134.72, 133.27, 131.98, 130.47, 130.13, 130.04, 129.14, 129.00, 128.03, 125.42, 124.14, 120.50, 119.37, 119.29, 116.78, 116.69, 97.97, 59.54, 53.95, 49.72, 43.03, 38.82, 38.42, 34.03, 33.87, 24.09, 23.59, 14.76, 11.26.

HRMS (m/z): [M+H]⁺calcd. for C₄₆H₄₅BF₂N₁₃O₈⁺, 956.3575; found: 956.3565.

¹H NMR, ¹³C NMR Spectra of New Compounds Compound 3.1



Compound 4



Intermediate of compound 6



Intermediate of compound 7









Probe 1R





Probe 1S









References

[S1]. M. L. Peterson, R. Vince, J. Med. Chem. 1991, 34, 2781-2797.
[S2]. Z. Pan, H. Scheerens, S. J. Li, B. E. Schultz, P. A. Sprengeler, L. C. Burrill, R. V. Mendonca, M. D. Sweeney, K. C. K. Scott, P. G. Grothaus, D. A. Jeffery, J. M. Spoerke, L. A. Honigberg, P. R. Young, S. A. Dalrymple, J. T. Palmer, ChemMedChem, 2007, 2, 58 – 61.

Biology

General Information

Regular reagents and reduced L-Glutathione were purchased from Sigma-Aldrich. Albumin Bovin V was purchased from Scientific Research Special. Protein marker (10022139), and other SDS-polyacrylamide gel preparing reagents were purchased from Bio-Rad. ECL Plus A + B (P0018) and other Tris-HCl buffers were purchased from Beyotime. Rmp Protein ASepharose Fast Flow (17-5138-01) was purchased from GE Healthcare.

Btk-1(kinase domain, 382-659) and Btk-1* (C481A, 382-659) were provided by Crown Bioscience Inc. Recombinant kinase EGFR (PV3872) was purchased from Life InvitrogenTM. Recombinant kinases Itk (08-181), Btk (08-080), Lck (08-170) were purchased from Carna Biosciences. Anti-Btk (3533S, 8547S) and anti-Itk (2380S) antibodies were purchased from Cell Signaling Technology. Anti-Btk (558527) antibody was purchased from BD Pharmingen. The secondary antibody against rabbit(sc-2004) and mouse(sc-2005) were purchased from Santa Cruz Biotechnology. NorthernLightsTM Anti-mouse IgG-NL557(NL007) were purchased from R&D Systems, Inc.

Cell lines(Namalwa, Raji, Jurkat) were purchased from Type Culture Collection of the Chinese Academy of Science, Shanghai, China and K562 was a gift from Prof. Shuo Lin's lab at Peking University Shenzhen Graduate School. All cell lines were cultured in RPMI 1640 medium (A10491, Invitrogen, Carlsbad, CA) containing 10% heat-inactivated fetal bovine serum (10099-141, Invitrogen, Carlsbad, CA), 100 units/ml penicillin, and 100 µg/ml streptomycin (C0222, Beyotime) and cultured in a

humidified 37°C incubator with 5% CO₂.CellTiter-Glo[®] Luminescent Cell Viability Assay Kit(G7572) was purchased from Promega.

All the fluorescence intensity analysis were recorded by Perkin Elmer Envision 2104 Multilabel Reader (Ex = 485 nm, Em = 520 nm) using OptiPlateTM–384F. Luminescence analysis was recorded by Tecan Microplate Reader InfiniteTM F200 using i-controlTM software.

All the fluorescence gel scanning was conducted with PharasFXTM Plus Molecular Imager (Bio-Rad, Ex = 480 nm and Em = 530 nm) using Quantity OneTM software.

Fluorescence microscopic images were acquired using a YOKOGAWA CV1000 confocal laser scanning microscope equipped with a X40 lens (Ex = 480 nm, Em =

520 nm) or a Zeiss Axio Observer A1 microscope equipped with charged coupled device.

Fluorescent Properties Measurements

Probes were dissolved in DMSO at 10 mMas stock solutions. For the fluorescence quenching efficiency analysis, probe solutions were diluted to 1 μ M in D-PBS and the fluorescence intensity was recorded by Perkin Elmer Envision 2104 Multilabel Reader (Ex = 485 nm, Em = 520 nm) using OptiPlateTM – 384F. For the fluorescence "turn-on" assays, purified recombinant Btk-1(kinase domain 382-659) or other surrogates (BSA or GSH) for free thiols was diluted to the final concentrations in reaction buffer (50 mM HEPES, 250 mM NaCl, 5% glycerol, 10 mM MgCl₂, 2 mM DTT, pH 8); probes1 and 2 were diluted to the desired concentrations by the reaction buffer. The fluorescence recovery was monitored and recorded by Perkin Elmer Envision 2104 Multilabel Reader (Ex = 485 nm, Em = 520 nm) using OptiPlateTM –

384F at 25 °C. In the competition experiments, Btk inhibitor ibrutinib was diluted to desired concentrations in reaction buffer and pre-incubated with Btk-1 at room temperature for 45 min, probe 1 or 2 was then added subsequently. The fluorescence intensity was calculated as $I_F/I_{F'}$, I_F : fluorescence intensity of Btk-1 and probes1 or 2, $I_{F'}$: fluorescence intensity of probe 1 or 2alone in reaction buffer.

Probe 1 in DMSO was added to Btk-1 solution at the final concentration of 0.5μ M (probe 1) and 25μ M (Btk-1) and the emission spectrum of the reaction system was recorded by BioTekR Synergy H1 Hybrid Reader at different time points (0.5h, 1h, 3h, 6h, 10h).



Supporting Figure 1. Fluorescent properties of probe 1 and 2. a) Time curve of fluorescence increase of 0.5 μ M probe 1 with 25 μ M Btk-1 with different concentrations of ibrutinib (12.5 μ M , 25 μ M , 37.5 μ M , 50 μ M). b) Time curve of fluorescence increase of 0.5 μ M probe 2 with 25 μ M Btk-1 with different concentrations of ibrutinib (12.5 μ M , 25 μ M , 37.5 μ M , 50 μ M). c) Time curve of

fluorescence increase of 0.5μ M probe 1 and 2 with 25μ M BSA. d) Time curve of fluorescence increase of 0.5μ M probe 1 and 2 with 15mM GSH. e) Emission spectrum of 0.5μ M probe 1 with 25μ M Btk-1 at different time.

Mass Spectrometry Study

Btk kinase domain (382-659) was labelled with probe 1 under the following conditions: 2 μ l of 9 mg/ml Btk kinase domain in Btk kinase domain buffer(50 mM HEPES, pH 8.0, 250 mM NaCl, 5% glycerol, 10 mM MgCl₂, 2 mM DTT) and 5.6 μ l of 1 mM probe 1 in DMSO were added to 92.4 μ l of 50 mM pH 8.0 HEPES buffer, and incubated at room temperature for 15 hrs. After the labelling, 0.6 μ g trypsin was

added to the labelling system and incubated at 37° C for 8 hrs. The digested peptides were loaded onto a LC-MS/MS system (Waters Acquity UPLC- Waters XEVO G2 QTOF). ESI-MS spectra were processed using the software Waters Biopharma Lynx 1.3.



Supporting Figure 2. Mass spectrum of the peptide fragment modified by probe 1.

In Vitro and Live Cell Probe Labelling Experiments

Recombinant kinases were diluted to the final concentrations in reaction buffer (50 mM HEPES, 250 mM NaCl, 5% glycerol, 10 mM MgCl₂, 2 mM DTT, pH 8) and incubated with various concentrations of probe1 for 3 hrs at room temperature, unless indicatedotherwise. Labelling was stopped by the addition of LDS Sample Buffer (NP0007, Invitrogen) and Sample Reducing Agent (NP0004, Invitrogen).

Cells (at a density of 1,500,000 cells/ml) in standard growth media were incubated with 2 μ Mprobe1 at 37°C in 5% CO₂ for 1h. Cells were washed with about 8X

volumes of PBS three times to remove serum proteins and excess probes, and the pellets were lysed directly in LDS Sample Buffer containing Sample Reducing Agent (NP0007 and NP0004, Invitrogen).

In competition experiments, purified proteins or live cells were incubated with inhibitors ibrutinib or compound 3 at 2 μ M for 45 min. Subsequently, the samples were labelled with probe 1as mentioned above.

Samples from in vitro protein and live cell labelling experiments were heated at

75°C for 10 minutes and 100°C for 20 minutes separately without removing of excess

probes. Then the denatured samples were resolved by SDS-polyacrylamide gels(12% or 10%), and the gels were visualized by fluorescence gel scanning with PharasFXTM Plus Molecular Imager (Bio-Rad, Ex = 480 nm and Em = 530 nm). The gels after scanning were transferred to poly(vinylidenedifluoride) membrane using Trans-Blot TurboTM Transfer system(Bio-Rad). Total Btk was detected using anti-Btk antibody and standard western blotting techniques.



Supporting Figure 3. Probe1 labelling of endogenous Btk in the lymphoma cell lines. a) Raji cells incubated with increasing concentrations of probe 1 for 1 hour. b) K562 cells incubated with increasing concentrations of probe 1 for 1 hour. c) Jurkat cells incubated with increasing concentrations of probe 1 for 1 hour. In Raji and K562 cells, two types of B cell lines, the predominant bandslabelled by the probe were at the expected MW of Btk, which was confirmed by Btk western blotting. In the Jurkat cell samples, no significant band was detected. Immunoblotting showed the presence of Itk in Jurkat cells, but not Btk.

Cell Viability Assays

Namalwa cells were seeded in 96-well plates (6,000 cells/well), then incubated with probe 1 for 48h; Lymphoma cells (Raji, K562, Jurkat cells) were seeded in 96-well plates (20,000 cells/well), then incubated with probe 1 for 12 h. After the planned

incubation time, cell viability was measured by the standard protocol of CellTiter-Glo[®] Luminescent Cell Viability Assay by Promega.



Supporting Figure 4. Probe **1** has minimal impact ontested cells'viability as detected by CellTiter-Glo[®] Luminescent Cell Viability Assay.a) Cell viability of Namalwa cells treated by probe **1** for 48h. b) Cell viability of Raji cells treated by probe **1** for 12h.c) Cell viability of K562 cells treated by probe **1** for 12h. d) Cell viability of Jurkat treated by probe **1** for 12h.

Probe 1, 1R and 1S Have Similar Labelling Effects



Probe 1 is a diastereomeric mixture containing chiral probes 1R and 1S. These probes were tested in labelling experiments with Btk protein and live Namalwa cells with similar procedures described above. Clearly, probes 1, 1R and 1S labelled Btk bands with similar intensities.



Supporting Figure 5.Comparision of Btk labelling by probe 1, 1R, 1S. a) Full length Btk labelling by probe 1, 1R, 1S. b) Endogenous Btk labelling by probe 1, 1R, 1S in live Namalwa cells.

No-wash Imaging of Btk in Live Cells

Namalwa cells were incubated with anti-human IgM at a final concentration of 4-5 mg/ml for 30 min to stimulate BCR signal transduction. Subsequently the stimulated cells were incubated with 1 μ M probe 1 and the images of Btk labelling by probe 1 in live cells were captured every 1 min immediately after the adding ofprobe1without extrawashing steps.



Supporting Figure 6. No-wash imaging of live Namalwa cells by probe 1 at different time points (0 min, 5 min, 10 min, 15 min, 20 min, 25 min). BF: Bright Field.

Brief Video

A minute-by-minute short video is available.

Competition Study

Namalwa cells at 1,000,000 cells per ml density were incubated with anti-human IgM at a final concentration of 4-5 mg/ml for 30 minutes to stimulate BCR signal transduction. The stimulated cells were incubated with 5 μ M competitor compound (compound **8** [IC₅₀=357nM] or ibrutinib [IC₅₀=22nM]) at 37°C 5% CO₂ for 1 hour. Subsequently the cells were incubated in competitor free medium and then incubated with 1 μ M probe 1 at 37°C 5% CO₂ for 1 hour. The cells were harvested, washed with PBS and then resuspended in PBS. The imaging data were captured at the same exposure time by fluorescent microscopy and processed with the same setting.



Supporting Figure 7. No-wash imaging of live Namalwa cells by probe 1 could be effectively competed out by either ibrutinib or compound 8. Scale bar: $10 \mu M$.

Jurkat cells at 1,000,000 cells per ml density were incubated with 1 μ M probe 1 at 37°C 5% CO₂ for 1 hour.The cells were harvested, washed with PBS and then resuspended in PBS. The imaging data were captured at the same exposure time by fluorescent microscopy and processed with the same setting.



Supporting Figure 8. No-wash imaging of live Jurkat cells (no Btk was expressed) by probe 1. Scale bar: 10 µM.

Co-localization Study

Namalwa cells at 1,000,000 cells per ml density were incubated with anti-human IgM at a final concentration of 4-5 mg/ml for 30 minutes to stimulate BCR signal transduction. Subsequently the stimulated cells were incubated with 1 μ M probe 1 at

37°C 5% CO₂for 1 hour. The cells were harvested, washed with PBS and then

resuspended in PBS. The cell suspension was then smeared to a gelatin-coated slide and fixed with 3.7% formaldehyde for 30 minutes. After washed with PBS, the cells were permeabilized with 0.5% Triton X-100 for 5 minutes, followed by blocking with

10% FBS. The cells were when incubated with anti-Btk antibody at 4°C overnight,

washed with PBS, labelled with Northern LightsTM Anti-mouse IgG-NL557, and washed with PBS. Pearson's correlation coefficient was calculated by ImageJTM as 0.90.